Aspirin and Enoxaparin for VTE in Trauma

Stopped early · Phase 4

Conditions studied: Venous Thromboembolism, Thromboprophylaxis, Trauma

In brief

The purpose of this study is to determine if the addition of antiplatelet therapy (i.e. aspirin) to low-molecular-weight-heparin (i.e. enoxaparin) will decrease the incidence of venous thromboembolism (VTE) in high-risk critically injured patients. The investigators further aim to determine the safety and efficacy of dual thromboprophylaxis with aspirin and enoxaparin for decreasing the incidence of VTE after trauma.

Key facts

Study ID

NCT02396732

Run by

University of Miami

People needed

31

Starts

2016-02-01

Expected to finish

2018-05-15

Last updated by the study team

2019-11-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 years or older
• Blunt or penetrating trauma
• Requires VTE thromboprophylaxis
• High-risk for VTE

You may not qualify if…

• Presence of VTE upon admission
• Pregnant or nursing
• Inability to give informed consent by patient or healthcare proxy
• Contraindication to enoxaparin
• Contraindication to aspirin
• Epidural or subdural hematoma
• Presence, or removal within the last 12 hours, of an epidural or spinal catheter, or recent (within the last 12 hours) epidural or spinal anesthesia/procedures

Where it is running

• Ryder Trauma Center — Miami, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.